ExonHit predicts 2009 US/EU filings for approval of AD (Alzheimer's disease) blood test:
This article was originally published in Clinica
Executive Summary
ExonHit Therapeutics is aiming to apply for the approval of its Alzheimer's disease (AD) blood test in both Europe and the US in 2009. So far, the multigene expression test has been shown to distinguish those with AD from those that have no cognitive impairment. In upcoming studies, the Paris, France firm hopes to prove that the test can differentiate AD from other brain pathologies, such as front temporal dementia, vascular dementia, Parkinson's disease, and also reversible dementias. Initially, the company hopes to market its test in Europe to pharma companies, for use in drug development. Following this, it plans to license the commercial rights to the test to one or more in vitro diagnostic companies. ExonHit claims that some 28 million people suffer from AD worldwide.